Hematological OncologyThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2 3

120 records returned

Outcomes for lymphoid malignancies in the Nurses' Health Study (NHS) as compared to the Surveillance, Epidemiology and End Results (SEER) ProgramEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Vital statistics for the lymphoid malignancies obtained from the Surveillance, Epidemiology and End Results (SEER) Program have seldom been directly compared to data from alternative national databases. While SEER is recognized as the standard, some lymphoid malignancies - especially the chronic ones - may be underreported. We compared the incidence, all-cause and cause-specific mortality for Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) in SEER to that in the Nurses' Health Study (NHS), a national cohort study of 121 700 female registered nurses, match...
Source: Hematological Oncology - October 28, 2009 Category: Hematology Authors: Gregory A Abel, Kimberly A Bertrand, Craig C Earle, Francine Laden Source Type: journals

Silibinin can induce differentiation as well as enhance vitamin D3-induced differentiation of human AML cells ex vivo and regulates the levels of differentiation-related transcription factorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Induction of terminal differentiation is a conceptually attractive approach for the therapy of neoplastic diseases. Although vitamin D derivatives (deltanoids) can induce differentiation of AML cells in vitro, so far deltanoids have not been successfully brought to the clinic, due to the likelihood of life-threatening hypercalcemia. Here, we incubated freshly obtained blood cells from patients with AML with a plant antioxidant (PAOx), silibinin (SIL), alone or together with a deltanoid. Twenty patients with AML (all subtypes except M3) were available for this study, and in 14 (70%), SIL (60 µM) either induced differentiat...
Source: Hematological Oncology - October 28, 2009 Category: Hematology Authors: Jing Zhang, Jonathan S Harrison, Milan Uskokovic, Michael Danilenko, George P Studzinski Source Type: journals

Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approachEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Burkitt Lymphoma (BL) is listed in the World Health Organization (WHO) classification of lymphoid tumours as an 'aggressive B-cell non-Hodgkin's lymphoma', characterized by a high degree of proliferation of the malignant cells and deregulation of the c-MYC gene. The main diagnostic challenge in BL is to distinguish it from diffuse large B-cell lymphoma (DLBCL). While in children BL and DLBCL types probably do not differ clinically, and the differential diagnosis between BL and DLBCL may theoretically appear clear-cut, in adults daily practice shows the existence of cases that have morphological features, immunophenotypic a...
Source: Hematological Oncology - October 20, 2009 Category: Hematology Authors: Cristiana Bellan, Lazzi Stefano, De Falco Giulia, Emily A Rogena, Leoncini Lorenzo Source Type: journals

Clofarabine in the treatment of poor risk acute myeloid leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, clofarabine (alone or in combination) is active in poor risk AML with an acceptable safety profile and should be considered a potential option in poor risk AML patients. Copyright © 2009 John Wiley & Sons, Ltd. (Source: Hematological Oncology)
Source: Hematological Oncology - September 17, 2009 Category: Hematology Authors: Janusz Krawczyk, Naeem Ansar, Ronan Swords, Tracy Murphy, Barry MacDonagh, Teresa Meenaghan, Patrick Hayden, Amjad Hayad, Margaret Murray, Michael O'Dwyer Source Type: journals

Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We analysed the dynamic change of imatinib-resistant mutations in BCR-ABL kinase domain focusing on T315I mutation during dasatinib or nilotinib therapy. Fifty-five imatinib-resistant chronic myeloid leukaemia patients (32 patients with imatinib-resistant mutations and 23 patients without mutation) in different disease phases were treated with dasatinib (median 17.3 months) or nilotinib (median 6.8 months). Among the 32 patients with baseline mutation, mutations including M244V, G250E, E255K, M351T, H396R, S417Y, E450K and E459K disappeared in 8 patients and new mutations were detected in 9 patients, all of which were T315...
Source: Hematological Oncology - September 17, 2009 Category: Hematology Authors: Wan-Seok Kim, Dongho Kim, Dong-Wook Kim, Il-Young Kweon, Soo-Hyun Kim, Hyun-Gyung Goh, Sa-Hee Park, Jeong Lee Source Type: journals

Severe pulmonary complications after bortezomib treatment in multiple myelomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
No Abstract. (Source: Hematological Oncology)
Source: Hematological Oncology - September 2, 2009 Category: Hematology Authors: Xiaoyi Dun, Zhengang Yuan, Weijun Fu, Chunyang Zhang, Jian Hou Source Type: journals

CT-guided percutaneous lung biopsies in patients with haematologic malignancies and undiagnosed pulmonary lesionsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We searched the electronic patient database at The University of Texas M. D. Anderson Cancer Center for patients who underwent computed tomography (CT)-guided needle biopsy between January 2001 and December 2005. Inclusion criteria were a known history of haematologic malignancy and a newly detected, undiagnosed pulmonary lesion on chest CT that required tissue sampling for diagnosis; 213 met these criteria. We analysed the biopsy results for diagnostic yield, factors affecting diagnostic yield and effect on treatment. Of 213 procedures, 191 (89.7%) yielded sufficient material for pathologic analysis; 130 (60%) yielded spe...
Source: Hematological Oncology - September 2, 2009 Category: Hematology Authors: Sanjay Gupta, Mark Sultenfuss, Jorge E. Romaguera, Joe Ensor, Savitri Krishnamurthy, Michael J. Wallace, Kamran Ahrar, David C. Madoff, Ravi Murthy, Marshall E. Hicks Source Type: journals

Geographic variation and environmental conditions as cofactors in Chlamydia psittaci association with ocular adnexal lymphomas: a comparison between Italian and African samplesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study was designed to investigate the possible association of Chlamydia psittaci in cases retrieved from Kenya, compared to cases from Italy. Our results showed that there was a marked variation between the two geographical areas in terms of association with C. psittaci, as 17% (5/30) of the samples from Italy were positive for C. psittaci, whereas no association with this pathogen was observed in any of the African samples (0/9), suggesting that other cofactors may determine the OAL occurrence in those areas. OAL cases are often characterized by down-regulation of p16/INK4a expression and promoter hypermethylation of...
Source: Hematological Oncology - September 2, 2009 Category: Hematology Authors: Alessandro Carugi, Anna Onnis, Giuseppina Antonicelli, Benedetta Rossi, Susanna Mannucci, Anna Luzzi, Stefano Lazzi, Cristiana Bellan, Gian Marco Tosi, Shaheen Sayed, Giulia De Falco, Lorenzo Leoncini Source Type: journals

Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard doseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report the outcome of 45 CML patients in early (17) and late (28) chronic phase (CP) in whom, within a series of 250 patients treated with imatinib, reduced the dose of the drug after experiencing adverse events. Median time interval between the start of therapy and dose reduction was 58 days, whereas median administered dose was 300 mg/day. At 6 months from reduction, major cytogenetic responses (MCRs) were observed in 67% of patients, with 58% being complete cytogenetic remission (CCR), and complete molecular response (CMR) were obtained in 18% of patients. At 12 months, all patients who had obtained MCR reached CCR: ...
Source: Hematological Oncology - September 2, 2009 Category: Hematology Authors: Massimo Breccia, Laura Cannella, Caterina Stefanizzi, Roberto Latagliata, Mauro Nanni, Daniela Diverio, Michelina Santopietro, Vincenzo Federico, Giuliana Alimena Source Type: journals

Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript - results of Polish multicentre studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, significant clinical symptoms are infrequent present and splenomegaly remains the most common organ involvement in patients with CEL expressing F/P fusion transcript. Our study confirmed the long-term remission on imatinib in this patient population. Copyright © 2009 John Wiley & Sons, Ltd. (Source: Hematological Oncology)
Source: Hematological Oncology - September 2, 2009 Category: Hematology Authors: Grzegorz Helbig, Andrzej Moskwa, Marek Hus, Jaros[lstrok]aw Piszcz, Alina Swiderska, Alina Urbanowicz, Ma[lstrok]gorzata Ca[lstrok]becka, Justyna Gajkowska, Ilona Sefery[nacute]ska, Magdalena Ha[lstrok]asz, Dariusz Woszczyk, Miroslaw Markiewicz, S[lstrok] Source Type: journals

Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approachEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Burkitt Lymphoma (BL) is listed in the World Health Organization (WHO) classification of lymphoid tumours as an "aggressive B-cell non-Hodgkin's lymphoma", characterized by a high degree of proliferation of the malignant cells and deregulation of the c-MYC gene. The main diagnostic challenge in BL is to distinguish it from diffuse large B-cell lymphoma (DLBCL). While in children BL and DLBCL types probably do not differ clinically, and the differential diagnosis between BL and DLBCL may theoretically appear clear-cut, in adults daily practice shows the existence of cases that have morphological features, immunophenotypic a...
Source: Hematological Oncology - August 10, 2009 Category: Hematology Authors: Cristiana Bellan, Lazzi Stefano, De Falco Giulia, Emily A. Rogena, Leoncini Lorenzo Source Type: journals

Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Chemotherapy regimens used for remission induction in AML have not changed significantly over the last several decades. However the recognition of the prognostic value of cytogenetics and genomics has been a major advance which is helping clarify the most optimal post-remission consolidation strategy among various risk groups. We are not only beginning to realize the pitfalls of a 'one-fits-all' approach with intensive, cytarabine-based chemotherapy as the mainstay, but we are finally beginning to reap the rewards of decades of basic, translational, and clinical research. Developing individualized, 'targeted' therapy for e...
Source: Hematological Oncology - July 30, 2009 Category: Hematology Authors: Mehdi Hamadani, Farrukh T. Awan Source Type: journals

The root of many evils: indolent large granular lymphocyte leukaemia and associated disordersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Large granular lymphocytes (LGL) leukaemia can arise from either natural killer (NK) cells or cytotoxic T lymphocytes (CTL). The T-cell form of LGL leukaemia has significant overlap with other haematological disorders and autoimmune diseases. Here we provide an overview of LGL biology. We also focus discussion on the indolent LGL leukaemia related disorders and their causal relationships. We then discuss the potential relationships and distinctions between indolent LGL leukaemia and non-malignant clonal lymphocyte expansion that occur in otherwise healthy individuals, especially elder people. Copyright © 2009 John Wiley &...
Source: Hematological Oncology - July 30, 2009 Category: Hematology Authors: Ranran Zhang, Mithun Vinod Shah, Thomas P. Loughran Jr Source Type: journals

18F-FDG uptake and its clinical relevance in primary gastric lymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, PET/CT scan can be used in staging patients with primary gastric lymphoma; however, the residual 18F-FDG uptake observed during follow-up should be interpreted cautiously and should be combined with endoscopy and multiple biopsies of the stomach. Copyright © 2009 John Wiley & Sons, Ltd. (Source: Hematological Oncology)
Source: Hematological Oncology - July 10, 2009 Category: Hematology Authors: Jun Ho Yi, Seok Jin Kim, Joon Young Choi, Young Hyeh Ko, Byung-Tae Kim, Won Seog Kim Source Type: journals

Experimental and clinical characteristics in myelodysplastic syndrome patients with or without HLA-DR15 alleleEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We studied the effects of the presence of the HLA-DR15 allele on the experimental and clinical features of myelodysplastic syndrome (MDS) by assessing the clinical data of 136 patients with MDS. We observed that the frequency of HLA-DR15 expression in MDS patients (38.7%) was significantly higher than that in the healthy controls (p < 0.01). We noted the following observations with regard to disease progression: None of the 46 HLA-DR15 positive patients with international prognostic scoring system (IPSS) scores [le]1 developed acute myeloid leukaemia (AML) during the follow-up period, while six of the 63 DR15-negative pati...
Source: Hematological Oncology - July 9, 2009 Category: Hematology Authors: Li Xiao, Liao Qiong, Zhang Yan, Zhang Zheng, Song Luxi, Xu Li, Tao Ying, Liu Yizhi, Pu Quan Source Type: journals

Two novel NPM1 mutations in a therapy-responder AML patientEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We describe a case of a therapy-responder acute myeloid leukaemia (AML) patient bearing two novel NPM1 mutations. Cells' transfection studies indicate that the presence of one of these mutations is associated to an abnormal nucleolar structure, suggesting that NPM1 may contribute to the control of nucleolar integrity. Copyright © 2009 John Wiley & Sons, Ltd. (Source: Hematological Oncology)
Source: Hematological Oncology - July 9, 2009 Category: Hematology Authors: Annalisa Pianta, Dora Fabbro, Daniela Damiani, Mario Tiribelli, Renato Fanin, Alessandra Franzoni, Milena Romanello, Gianluca Tell, Carla Di Loreto, Giuseppe Damante Source Type: journals

Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entityEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nucleophosmin (NPM) is a ubiquitously expressed chaperone protein that shuttles rapidly between the nucleus and cytoplasm, but predominantly resides in the nucleolus. It plays key roles in ribosome biogenesis, centrosome duplication, genomic stability, cell cycle progression and apoptosis. Somatic mutations in exon 12 of the NPM gene (NPM1) are the most frequent genetic abnormality in adult acute myeloid leukaemia (AML), found in approximately 35% of all cases and up to 60% of patients with normal karyotype (NK) AML. In children, NPM1 mutations are far less frequent, occurring in 8-10% of all AML cases, and in approximatel...
Source: Hematological Oncology - June 30, 2009 Category: Hematology Authors: Rachel Rau, Patrick Brown Source Type: journals

Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Telomeres are specialized structures localized at the end of human chromosomes. Due to the end replication problem, each cell division results in a loss of telomeric repeats in normal somatic cells. In germ line and stem cells, the multicomponent enzyme telomerase maintains the length of telomere repeats. However, elevated telomerase activity has also been reported in the majority of solid tumours as well as in acute and chronic leukaemia. Chronic myeloid leukaemia (CML) serves as a model disease to study telomere biology in clonal myeloproliferative disorders. In CML, telomere shortening correlates with disease stage, dur...
Source: Hematological Oncology - June 30, 2009 Category: Hematology Authors: Gunhild Keller, Ute Brassat, Melanie Braig, Denise Heim, Henning Wege, Tim H. Brümmendorf Source Type: journals

How would I manage a sample submitted for flow cytometry analysis for suspicious chronic lymphocytic leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Samples submitted for a suspect of chronic lymphocytic leukemia are the most frequently observed in flow cytometry laboratories. These cases require not only a precise and prompt diagnosis but also an evaluation on the possibility of performing additional prognostic tests. We will propose two sequential flow cytometry panels and a personal opinion on how to manage these samples for both diagnostic and prognostic assessment, taking into account the published guidelines and recommendations. Copyright © 2009 John Wiley & Sons, Ltd. (Source: Hematological Oncology)
Source: Hematological Oncology - June 30, 2009 Category: Hematology Authors: Pietro Bulian, Giovanni Del Poeta, Valter Gattei Source Type: journals

New antimicrobial agents for the treatment of bacterial infections in cancer patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Patients with cancer develop serious bacterial infections often, especially during periods of severe and prolonged neutropenia. Antibiotic usage for the prevention and treatment of bacterial infections in these high-risk patients leads to selection pressures resulting in the emergence and spread of resistant organisms. Many organisms acquire several resistance mechanisms, making them multi-drug-resistant (MDR) (defined as resistance to three or more different classes of antibiotics). These infections are associated with increased morbidity, mortality and costs. The development of novel antimicrobial agents with activity ag...
Source: Hematological Oncology - June 30, 2009 Category: Hematology Authors: Kenneth V. I. Rolston Source Type: journals

Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, 61% of PMF patients developed RBC-TD which portended inferior OS; however patients receiving ICT had comparatively improved OS, suggesting a clinical benefit. Prospective studies of IOL and the impact of ICT in PMF are warranted. Copyright © 2009 John Wiley & Sons, Ltd. (Source: Hematological Oncology)
Source: Hematological Oncology - June 24, 2009 Category: Hematology Authors: Heather A. Leitch, Jocelyn M. Chase, Trisha A. Goodman, Hatoon Ezzat, Meaghan D. Rollins, Dominic H.C. Wong, Maha Badawi, Chantal S. Leger, Khaled M. Ramadan, Michael J. Barnett, Lynda M. Foltz, Linda M. Vickars Source Type: journals

Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The current study aimed to evaluate the efficacy and toxicity of a combination of intravenous (iv) busulfan (Bu) and continuous infusion Idarubicin (IDA) as a conditioning regimen to autologous haematopoietic stem cell transplantation (ASCT) in patients with acute myeloid leukaemia (AML). The protocol included IDA at 20 mg/sqm daily as 3 days continuous infusion (from day -13 to -11) and intravenous BU at 3.2 mg/kg daily from day -5 to -2. Patients aged over 60 years received a reduced schedule (2 days IDA and 3 days BU at the same dose). Twenty-five patients with a median age of 51 years (28-72) were enrolled. All patient...
Source: Hematological Oncology - May 30, 2009 Category: Hematology Authors: Felicetto Ferrara, Giuseppina Mele, Salvatore Palmieri, Mariangela Pedata, Carolina Copia, Cira Riccardi, Tiziana Izzo, Clelia Criscuolo, Pellegrino Musto Source Type: journals

The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The prognosis of diffuse large B-cell lymphoma (DLBCL) has improved markedly in recent years of rituximab era. The prognosis of de novo CD5-positive DLBCL is reported to be poor, but the effect of rituximab on this type of lymphoma remains unclear. To investigate the effect of rituximab on CD5-positive DLBCL, we collected DLBCL patients and analysed prognostic factors. A total of 157 patients with DLBCL who were immunophenotyped with flow-cytometry (FCM) and treated with chemotherapy were subjected to analysis. Those treated with radiotherapy alone or with supportive therapy only were not included. Patients diagnosed in 20...
Source: Hematological Oncology - April 17, 2009 Category: Hematology Authors: Rie Hyo, Naoto Tomita, Kengo Takeuchi, Tomohiro Aoshima, Atsuko Fujita, Hideyuki Kuwabara, Chizuko Hashimoto, Sachiya Takemura, Jun Taguchi, Rika Sakai, Hiroyuki Fujita, Shin Fujisawa, Koji Ogawa, Shigeki Motomura, Ritsuro Suzuki, Yoshiaki Ishigatsubo Source Type: journals

Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian populationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, this study represents the first report of NPM1 mutation from Indian population and confirms that the incidence of NPM1 mutations varies considerably globally, with slightly lower incidence in Indian population compared to western countries. The current study also served to identify two novel NPM1 mutants that add new insights into the heterogeneity of genomic insertions at exon 12. More ongoing larger studies are warranted to elucidate the molecular pathogenesis of AML that arises in this part of the world. Furthermore, we believe that in light of its high prevalence worldwide, inclusion of NPM1 mutation det...
Source: Hematological Oncology - April 13, 2009 Category: Hematology Authors: Firoz Ahmad, Swarna Mandava, Bibhu Ranjan Das Source Type: journals

The role of stem cell transplantation in the management of chronic lymphocytic leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The majority of patients diagnosed with chronic lymphocytic leukaemia (CLL) will ultimately die of their disease. Stem cell transplantation (SCT) remains the only treatment modality capable of cure, but has traditionally been associated with very high morbidity and mortality. We review the results of myeloablative autologous and allogeneic SCT in CLL, discuss the evolution of the new non-myeloablative approaches, and make recommendations for when SCT should be considered in patients with CLL. Copyright © 2009 John Wiley & Sons, Ltd. (Source: Hematological Oncology)
Source: Hematological Oncology - April 8, 2009 Category: Hematology Authors: Constantine S. Tam, Issa Khouri Source Type: journals

Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Anaplastic large cell lymphoma (ALCL) is a subtype of peripheral T-cell lymphoma (PTCL) first described in 1985 as a lymphoid malignancy characterized by marked cellular pleomorphism, propensity to grow cohesively, tendency to invade lymph node sinuses and diffuse expression of CD30 . The discovery of the t(2;5), involving the anaplastic lymphoma kinase (ALK) gene on chromosome 2 and the nucleophosmin (NPM) gene on chromosome 5 in the majority of systemic ALCL, has soon pointed out that ALCL is a clinically and biologically heterogeneous disease. While ALK-positive (ALK+) ALCL is usually characterized by onset in children ...
Source: Hematological Oncology - April 8, 2009 Category: Hematology Authors: Alessandro Fornari, Roberto Piva, Roberto Chiarle, Domenico Novero, Giorgio Inghirami Source Type: journals

KHSV- EBV- post-transplant effusion lymphoma with plasmablastic features: variant of primary effusion lymphoma?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report a unique KSHV- EBV- post-transplant effusion lymphoma associated with serum paraproteins, occurring in an HIV- individual, which had cytologic features and phenotype similar to PEL, and displayed a complex karyotype including isochromosome 12p and translocation t(8;22), resulting in rearrangement of c-MYC. Copyright © 2009 John Wiley & Sons, Ltd. (Source: Hematological Oncology)
Source: Hematological Oncology - April 7, 2009 Category: Hematology Authors: Jennifer S. Lambe, Darryl A. Oble, Subhadra V. Nandula, Deborah W. Sevilla, Adriana I. Colovai, Mahesh Mansukhani, Ajai Chari, Vundavalli V. Murty, Bachir Alobeid, Govind Bhagat Source Type: journals

Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trialEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: These preliminary data showed that adoptive immunotherapy with CIK cells is a safe therapy with some suggestion of efficacy that significantly enhances immune functions increasing absolute numbers of effector cells without side effects. If confirmed in larger scale studies, these promising results may have a favourable impact on conventional treatment strategy of malignancies. Copyright © 2009 John Wiley & Sons, Ltd. (Source: Hematological Oncology)
Source: Hematological Oncology - March 17, 2009 Category: Hematology Authors: Paola Olioso, Raffaella Giancola, Maria Di Riti, Alessandro Contento, Patrizia Accorsi, Antonio Iacone Source Type: journals

Radiological findings of early invasive pulmonary aspergillosis in immune-compromised patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study describes the radiological features of early stages of IPA. Chest computerized tomography (CT) films of 22 consecutive immune-compromised patients with IPA diagnosed with the aid of ASP PCR testing from BAL fluid were characterized and compared to that of 18 similar patients diagnosed with traditional bacteriological methods and to data from the literature. It was found that patients diagnosed with the aid of ASP PCR testing tended to have focal disease as manifested by more 11-30 mm nodules with halo (68% vs. 33%, p = 0.04), more focal ground glass (single area 32% vs. 6%, p = 0.05, patchy 32% vs. 0%, p = 0.01)...
Source: Hematological Oncology - March 17, 2009 Category: Hematology Authors: OR Brook, L Guralnik, E Hardak, I Oren, H Sprecher, T Zuckerman, A Engel, M Yigla Source Type: journals

Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in Elderly acute myeloid leukaemia patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Elderly acute myeloid leukaemia (AML) patients have a dismal prognosis due to biological features of disease in itself and to presence of comorbidities. Aim of this study was to evaluate the prognostic impact of comorbidity prognostic score systems applied in our population of patients. as well as other clinical-biological features. We retrospectively considered the outcome of 120 patients aged >65 years diagnosed as having AML between January 2001 and December 2005. Comorbidities were evaluated by using Charlson comorbidity index (CCI), Hematopoietic cell transplantation comorbidity index (HCTCI) and a score proposed by D...
Source: Hematological Oncology - March 11, 2009 Category: Hematology Authors: Massimo Breccia, Anna Maria Frustaci, Laura Cannella, Caterina Stefanizzi, Roberto Latagliata, Claudio Cartoni, Daniela Diverio, Anna Guarini, Mauro Nanni, Angela Rago, Giuseppe Cimino, Giuliana Alimena Source Type: journals

MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Acquired mutations in the juxtamembrane region of MPL (W515L or W515K), the receptor for thrombopoietin, have been reported in patients with primary essential thrombocythemia (ET) or primary myelofibrosis (PMF). The mutations were detected by the newly developed real-time quantitative PCR (RQ-PCR) with TaqMan MGB probes and followed by the sequencing analysis. DNA samples were from 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders (cMPDs). Reference curves were obtained using cloned fragments of MPL containing either the wild-type or MPL W515L or MPL W515K mutated sequence; the predic...
Source: Hematological Oncology - March 8, 2009 Category: Hematology Authors: Guo-Rui Ruan, Bin Jiang, Ling-Di Li, Ji-Hong Niu, Jin-Lan Li, Min Xie, Ya-Zhen Qin, Yan-Rong Liu, Xiao-Jun Huang, Shan-Shan Chen Source Type: journals

Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Despite durable responses to imatinib in chronic myeloid leukaemia (CML), mutations in Bcr-Abl kinase domain (KD) are known to induce imatinib resistance and cause poor clinical outcome. We characterized Bcr-Abl KD mutations in 137 Korean CML patients with imatinib resistance (n = 111) or intolerance (n = 26) using allele specific oligonucleotide polymerase chain reaction (PCR) and direct sequencing. Seventy (51%) patients harboured 81 mutations of 20 different types with increasing prevalence in advanced phase. Nine (13%) patients had multiple mutations. No mutation was found in intolerant patients. T315I was the most com...
Source: Hematological Oncology - March 8, 2009 Category: Hematology Authors: Soo-Hyun Kim, Dongho Kim, Dong-Wook Kim, Hyun-Gyung Goh, Se-Eun Jang, Jeong Lee, Wan-Seok Kim, Il-Young Kweon, Sa-Hee Park Source Type: journals

A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Mantle cell lymphoma (MCL) has a poor prognosis with often short and incomplete remissions. We aimed to test the efficacy and tolerability of gemcitabine in treating MCL. Gemcitabine was given in doses of 1000 mg/m2 as a 30 min infusion on days 1 and 8 of each 3 week cycle for a maximum of nine cycles. Eighteen patients with a median age of 70 years were recruited. MCL was newly diagnosed in half of patients and relapsed in the remainder. Fifteen patients had Ann Arbor stage IV. The best-recorded responses were 1 CR (complete remission), 4 PRs (partial responses), 8 SDs (stable diseases) and 4 PDs (diseases progression). T...
Source: Hematological Oncology - March 8, 2009 Category: Hematology Authors: F. Hitz, G. Martinelli, E. Zucca, R. von Moos, W. Mingrone, M. Simcock, J. Peterson, S. B. Cogliatti, F. Bertoni, D. R. Zimmermann, M. Ghielmini, on behalf of the Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland Source Type: journals

Involved field radiotherapy for limited stage Hodgkin lymphoma: balancing treatment efficacy against long-term toxicitiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Limited stage Hodgkin lymphoma (HL) refers to patients with stage IA or IIA disease in the absence of any bulky mass or unfavourable prognostic factors. In this group, the long-term disease control with treatment can be expected in more than 90%, and management has now been directed to make strategies to reduce late morbidities related to therapy. With the advent of very effective chemotherapy, the role of radiation therapy has evolved from a first line single modality treatment, to an adjuvant therapy following brief cycles of chemotherapy. Optimal radiation volume and dose parameters have been refined in the combined mod...
Source: Hematological Oncology - March 8, 2009 Category: Hematology Authors: Jayant S. Goda, Richard W. Tsang Source Type: journals

Low dose radiotherapy in indolent lymphomas, enough is enoughEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Follicular lymphomas, as a prototype of all indolent lymphomas, are exquisitely radiation sensitive. This review paper highlights the clinical presentation of this lymphoma entity. Literature data are presented on first line curative irradiation in stage I and II patients, low-dose total body irradiation (TBI) in stage III and IV patients in first line and low-dose IF-RT (involved field radiotherapy) in patients with relapse. The clinical aspects of 2 × 2 Gy IF-RT in follicular lymphoma (FL) are presented as well as the in vivo imaging of the apoptotic cell death underlying the clinical response. Finally, by gene expressi...
Source: Hematological Oncology - March 6, 2009 Category: Hematology Authors: R. L. M. Haas Source Type: journals

CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLLEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CD26 (dipeptidyl peptidase IV, DPP IV) is widely expressed by T and natural killer (NK) cells, epithelial and endothelial cells of different tissues, and it is strongly upregulated in activated B-cells; moreover it plays a regulatory role in the neoplastic transformation and progression of various types of tumours. CD26 expression was evaluated by means of flow cytometry in various peripheral B-cell lymphoid tumours: 12 follicular and 12 mantle cell lymphomas, 20 multiple myelomas (MMs), 12 hairy cell leukaemias (HCLs), 112 chronic lymphocytic leukaemias (CLLs), 20 CD5negative B-cell chronic lymphoproliferative diseases (C...
Source: Hematological Oncology - February 26, 2009 Category: Hematology Authors: Lilla Cro, Fortunato Morabito, Nadia Zucal, Sonia Fabris, Marta Lionetti, Giovanna Cutrona, Francesca Rossi, Massimo Gentile, Andrea Ferrario, Manlio Ferrarini, Stefano Molica, Antonino Neri, Luca Baldini Source Type: journals

Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic optionsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Central nervous system (CNS) dissemination is a rare (4-5%) but usually fatal complication of aggressive lymphomas. Prophylaxis modalities to prevent CNS dissemination in aggressive lymphomas cannot be widely applied to every lymphoma patient since it is associated with increased risk of neurotoxicity. Therefore, identification of high-risk patients as the best candidates to receive CNS prophylaxis constitutes a major endpoint in the management of these malignancies. Various risk factors and models for CNS recurrence have been described. Parameters reflecting the extent and proliferation of the disease, like elevated serum...
Source: Hematological Oncology - February 26, 2009 Category: Hematology Authors: Andrés J. M. Ferreri, Andrea Assanelli, Roberto Crocchiolo, Fabio Ciceri Source Type: journals

T-cell CD38 expression in B-chronic lymphocytic leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
B-cell chronic lymphocytic leukaemia (B-CLL) is a heterogeneous disease with some patients having an indolent course never needs treatment, while others having rapidly progressive one requires intensive treatment. In recent decades, numerous prognostic markers, such as immunoglobulin variable region heavy-chain (IgVH) mutational status, ZAP-70 and the expression of CD38 on leukaemic cells were introduced to screen for patients likely to have progressive course of B-CLL bearing the potential to facilitate risk-adapted treatment strategies. In B-CLL, T cell function is shown to be dysregulated. CD38 has been demonstrated to ...
Source: Hematological Oncology - February 26, 2009 Category: Hematology Authors: Nashwa Khayrat Abousamra, Manal Salah EL-Din, Emad Azmy Source Type: journals

Determinants of peripheral blood count value in long-term survivors of allogeneic hemopoietic stem cell transplantationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Hemopoeitic stem cell transplant (HSCT) recipients are monitored by regular complete blood picture (CBP). The reference ranges for acceptable values are undefined. We analysed the CBP in 228 stable HSCT survivors (median follow-up 103 months, range 60-212) without transplant-related medications and complications. Compared with donors, recipients had lower absolute neutrophil count (ANC) and platelet levels (Plt) and higher mean corpuscular volume (MCV), but comparable hemoglobin (Hb) and absolute lymphocyte count (ALC). There was significant donor-recipient correlation in all CBP parameters (Hb, ALC, ANC, MCV, Plt). Signif...
Source: Hematological Oncology - February 26, 2009 Category: Hematology Authors: Koljonen A Paul, Lie Albert Kwok-wai, Liang Raymond, Au Wing-Yan Source Type: journals

Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphanEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report therapeutic results from a series of 40 AML patients older than 60 years (median age 67 years) autografted in first complete remission (CR), after conditioning with continuous infusion (c.i.) high dose idarubicin and busulphan. Fourty patients (median age: 67 years) received 2 days c.i. idarubicin at 20 mg/m2/day, followed by 3 days oral or intravenous busulphan (4 mg/kg/day) as conditioning. No case of transplant-related mortality occurred. Cardiac toxicity was absent, while 31 patients (77%) had grade 3-4 mucositis. After a median follow-up of 25 months, median disease free and overall survival (OS) for the who...
Source: Hematological Oncology - February 11, 2009 Category: Hematology Authors: Felicetto Ferrara, Salvatore Palmieri, Mariangela Pedata, Assunta Viola, Tiziana Izzo, Clelia Criscuolo, Giuseppina Mele Source Type: journals

High ratio of Duffy (a+b+) phenotype in patients with multiple myeloma compared to healthy controlsEmail this article to a colleague. Save this article to My Clippings. discuss this article 1 CommentDiscuss or comment on this article.
No Abstract. (Source: Hematological Oncology)
Source: Hematological Oncology - February 10, 2009 Category: Hematology Authors: Nil Guler, Mehmet Turgut, Duzgun Ozatli, Yasemin Turgut, Ayse Kevser Gokce, Salih Koc, Davut Albayrak Source Type: journals

Richter syndrome: molecular insights and clinical perspectivesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Richter syndrome (RS) represents the clinico-pathologic transformation of chronic lymphocytic leukaemia (CLL) to an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). The clinical definition of RS is heterogeneous, and encompasses at least two biologically different conditions: (i) CLL transformation to a clonally related DLBCL, that accounts for the majority of cases; (ii) development of a DLBCL unrelated to the CLL clone. In clonally related RS, the pathogenetic link between the CLL and the DLBCL phases is substantiated by the acquisition of novel molecular lesions at the time of clinico-pathologic...
Source: Hematological Oncology - February 10, 2009 Category: Hematology Authors: Davide Rossi, Gianluca Gaidano Source Type: journals

Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Classical Hodgkin Lymphoma (cHL) is morphologically characterized by a small number of tumour cells, Hodgkin and Reed-Sternberg (HRS) cells, surrounded by numerous tumour-infiltrating lymphocytes (TIL). The functional role of these TIL is still controversial. While generally considered to represent an anti-tumour immune response, TIL in cHL might result from the profoundly deregulated immunity of cHL patients. Eighty-seven cases of cHL were available to evaluate the prognostical significance of tumour-infiltrating cytotoxic T lymphocytes (CTL), T helper 1 (Th1) cells, T helper 2 (Th2) cells and regulatory T cells (Treg). W...
Source: Hematological Oncology - October 16, 2008 Category: Hematology Authors: Sabine Schreck, Daniela Friebel, Maike Buettner, Luitpold Distel, Gerhard Grabenbauer, Lawrence S. Young, Gerald Niedobitek Source Type: journals

Intravascular large B-cell lymphoma with FDG accumulation in the lung lacking CT/67gallium scintigraphy abnormalityEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this report, we present a case of IVLBCL with pulmonary involvement where 18-fluoro-deoxyglucose positron emission tomography (FDG-PET) was useful in the early diagnosis. Neither computed tomography (CT) nor 67gallium scintigraphy could reveal the presence of disease in the lung. Histological evidence of IVLBCL was obtained by TBLB after FDG uptake in the lung was confirmed by FDG-PET. The patient exhibited a good response to the subsequent combination chemotherapy. We propose that FDG-PET is a powerful tool for the early diagnosis of IVLBCL with pulmonary involvement, if the possibility of this disease presents in the ...
Source: Hematological Oncology - September 26, 2008 Category: Hematology Authors: Akira Kitanaka, Yoshitsugu Kubota, Osamu Imataki, Hiroaki Ohnishi, Tetsuya Fukumoto, Kazutaka Kurokohchi, Terukazu Tanaka Source Type: journals

Molecular targeting of the PKC-[beta] inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The protein kinase C (PKC) pathway has been shown to play a role in the regulation of cell proliferation in several haematological malignancies, including multiple myeloma (MM). Recent data have shown that a PKC inhibitor, enzastaurin, has antiproliferative and proapoptotic activity in a large panel of human myeloma cell lines (HMCLs). In order to further characterise the effect of enzastaurin in MM, we performed gene expression profiling of enzastaurin-treated KMS-26 cell line. We identified 62 upregulated and 32 downregulated genes that are mainly involved in cellular adhesion (CXCL12, CXCR4), apoptosis (CTSB, TRAF5, BCL...
Source: Hematological Oncology - September 2, 2008 Category: Hematology Authors: Donata Verdelli, Lucia Nobili, Katia Todoerti, Daniela Intini, Maria Cosenza, Monica Civallero, Jessika Bertacchini, Giorgio Lambertenghi Deliliers, Stefano Sacchi, Luigia Lombardi, Antonino Neri Source Type: journals

A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myelomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we investigated the effect of high dose simvastatin (HD-Sim) on biochemical markers of bone turnover and disease activity in six heavily pretreated patients with multiple myeloma (MM). These patients were treated with simvastatin (15 mg/kg/day) for 7 days followed by a rest period of 21 days in two 4-week cycles. Endpoints were changes in the level of biochemical markers of (i) osteoclast activity (tartrate resistant acid phosphatase, TRACP); (ii) bone resorption (collagen fragments CTX and NTX); (iii) bone formation (osteocalcin and aminoterminal propeptide of type I collagen PINP); (iv) cholesterol; (v) re...
Source: Hematological Oncology - August 1, 2008 Category: Hematology Authors: TE Sondergaard, PT Pedersen, TL Andersen, K Søe, T Lund, B Østergaard, P Garnero, J-M Delaisse, T Plesner Source Type: journals

Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Arsenic trioxide (As2O3) has established clinical activity in acute promyelocytic leukaemia and has pre-clinical data suggesting activity in lymphoid malignancies. Cell death from As2O3 may be the result of oxidative stress. Agents which deplete intracellular glutathione, such as ascorbic acid (AA), may potentiate arsenic-mediated apoptosis. This multi-institution phase II study investigated a novel dosing schedule of As2O3 and AA in patients with relapsed or refractory lymphoid malignancies. Patients received As2O3 0.25 mg/kg IV and AA 1000 mg IV for five consecutive days during the first week of each cycle followed by tw...
Source: Hematological Oncology - July 31, 2008 Category: Hematology Authors: JE Chang, PM Voorhees, JM Kolesar, HG Ahuja, FA Sanchez, GA Rodriguez, K Kim, J Werndli, HH Bailey, BS Kahl Source Type: journals

Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic LeukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Fludarabine plus cyclophosphamide (FC) at conventional doses is an effective treatment for chronic lymphocytic leukaemia (CLL). However, FC at standard doses may give hematological and non-hematological toxicity, predominantly in the elderly. Intravenous or oral low-dose FC regimens remain highly effective in elderly patients with Low-Grade Lymphomas other than CLL and are well tolerated. We tested efficacy and toxicity of oral FC at reduced doses in 26 elderly patients (median 71 years) with previously untreated (UT-CLL, n = 14) or relapsed/refractory CLL (R-CLL, n = 12), unfit for conventional treatments. Twentyfour-of-2...
Source: Hematological Oncology - July 22, 2008 Category: Hematology Authors: Francesco Forconi, Alberto Fabbri, Mariapia Lenoci, Elisa Sozzi, Alessandro Gozzetti, Maristella Tassi, Donatella Raspadori, Francesco Lauria Source Type: journals

Acute promyelocytic leukaemia and acquired [alpha]-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bleeding diathesis and a hyper-fibrinolytic state often accompany a diagnosis of Acute Promyelocytic Leukaemia (APML). This complication can have grave effects if not successfully treated, with a 10-20% incidence of haemorrhagic death. We hypothesized that [alpha]-2-antiplasmin levels would correlate with the risk for bleeding, and that administration of epsilon-aminocaproic acid (EACA) would attenuate that risk. To assess this, we conducted a retrospective chart review analyzing 30 APML patients, 17 of whom were treated with EACA. Thirty patients were treated, 21 with primary induction therapy. Patients with low [alpha]-2...
Source: Hematological Oncology - July 10, 2008 Category: Hematology Authors: T. Wassenaar, J. Black, B. Kahl, B. Schwartz, W. Longo, D. Mosher, E. Williams Source Type: journals

Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseasesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study by using a cytofluorimetric analysis we evaluated circulating endothelial progenitor cells (EPCs) in patients with chronic myeloproliferative disease. Moreover, in the same group of subjects, we evaluated serum levels of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor-2 (VEGFR2). In our patients, we have found an increase in the number of endothelial progenitor cells in primary myelofibrosis (PMF) and polycythaemia vera (PV) patients, while an increase of circulating endothelial cells (CECs) was found in all patients with CMD. Moreover, we found higher serum levels of...
Source: Hematological Oncology - May 27, 2008 Category: Hematology Authors: A Alonci, A Allegra, G Bellomo, G Penna, A D'Angelo, E Quartarone, C Musolino Source Type: journals